Charles J. Cohen

Burnaby, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

The venom of Cyriopagopus schmidti spider contains a natural huwentoxin-IV analogue with unexpected improved analgesic potential.

The venom of Cyriopagopus schmidti spider contains a natural huwentoxin-IV analogue with unexpected improved analgesic potential.

Journal: Frontiers in pharmacology

Published: January 24, 2025

Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7.

Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7.

Journal: Bioorganic & medicinal chemistry letters

Published: September 20, 2024

Molecular Pharmacology of Selective NaV1.6 and Dual NaV1.6/NaV1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo.

Molecular Pharmacology of Selective NaV1.6 and Dual NaV1.6/NaV1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo.

Journal: ACS chemical neuroscience

Published: February 15, 2024

The contribution of NaV1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and NaV1.6 gain-of-function (GOF) mouse seizure control.

The contribution of NaV1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and NaV1.6 gain-of-function (GOF) mouse seizure control.

Journal: British journal of pharmacology

Published: December 21, 2023

Structure-function relationship of new peptides activating human Nav1.1.

Structure-function relationship of new peptides activating human Nav1.1.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 23, 2023

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.

Journal: The Journal of pharmacology and experimental therapeutics

Published: September 01, 2022

Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human NaV1.7/NaV1.6 Selectivity Ratios.

Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human NaV1.7/NaV1.6 Selectivity Ratios.

Journal: Frontiers in cell and developmental biology

Published: October 20, 2021

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

Journal: eLife

Published: July 24, 2021

Identification of aryl sulfonamides as novel and potent inhibitors of NaV1.5.

Identification of aryl sulfonamides as novel and potent inhibitors of NaV1.5.

Journal: Bioorganic & medicinal chemistry letters

Published: April 07, 2021

Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310.

Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310.

Journal: Journal of medicinal chemistry

Published: March 08, 2021

Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.

Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.

Journal: Journal of medicinal chemistry

Published: September 19, 2019

Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.

Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.

Journal: Journal of medicinal chemistry

Published: April 04, 2019

Showing 1-12 of 25

Last Updated: 09/26/2026